Loading organizations...
Loading organizations...
EQRx is a technology company.
EQRx operates as a biotechnology company dedicated to re-engineering the process of drug discovery and development to deliver innovative medicines at significantly lower costs. The company focuses on identifying and advancing high-quality therapeutic candidates across prevalent disease areas, leveraging modern technological and scientific approaches to streamline traditional pharmaceutical pipelines. Its model aims to generate an expansive portfolio of new drugs designed for affordability from inception.
The company was founded in January 2020 by Alexis Borisy, a veteran entrepreneur and venture capitalist in the biotech sector. Borisy's founding insight stemmed from the recognition of escalating drug prices and the potential to disrupt the pharmaceutical industry's cost structures by adopting a new approach to R&D and commercialization. His extensive background provided a strong foundation for launching a company with such an ambitious mandate.
EQRx primarily serves patients and global healthcare systems by making essential medicines more accessible and sustainable. The company's long-term vision is to establish a new paradigm in pharmaceutical development, ensuring that medical innovations are not only effective but also universally affordable. It strives to broaden access to critical treatments, thereby improving patient outcomes and contributing to healthier populations worldwide.
EQRx has raised $700.0M across 2 funding rounds.
EQRx has raised $700.0M in total across 2 funding rounds.
EQRx has raised $700.0M in total across 2 funding rounds.
EQRx's investors include Andreessen Horowitz, Arboretum Ventures, ARCH Venture Partners, Casdin Capital, Krishna Yeshwant, Nextech, Section 32.
EQRx is a biotechnology company founded in 2019 in Cambridge, Massachusetts, focused on developing innovative medicines for high-cost diseases like cancer and inflammatory conditions, initially aiming to deliver them at radically lower prices through efficient processes.[1][2][3][5] It built a pipeline of over 10 programs, including late-stage oncology assets like aumolertinib and sugemalimab, while leveraging data science, tech integration, and partnerships to accelerate development.[2][3] The company raised $700M+ and went public via a SPAC merger valued at $1.8B, but faced setbacks, abandoning its low-price model, dropping key candidates, and undergoing major layoffs before its acquisition by Revolution Medicines in November 2023.[1][4]
EQRx targeted patients and payers in oncology and metabolic diseases, solving high drug costs and slow development by re-engineering the pharma process—focusing on validated biology, fast trials (initially in China), and end-to-end tech.[2][3] Growth peaked with VC backing from Andreessen Horowitz and Bain, but momentum stalled amid regulatory hurdles, strategy shifts, and market pressures, leading to its pivot and sale at the P2P stage.[1][4]
EQRx was co-founded in 2019 by Alexis Borisy, a serial biotech entrepreneur and investor, and Melanie Nallicheri, a biotech executive, with a mission to "remake medicine" by disrupting inefficient pharma R&D and pricing.[2][3] Borisy's track record in life sciences ventures and Nallicheri's operational expertise drove the vision for a tech-infused model to launch medicines faster and cheaper, inspired by Amazon-like process overhauls.[2] Early traction came from massive funding—over $1B in 2020-2021—including from a16z and a $1.8B SPAC with CM Life Sciences III in 2021, enabling rapid pipeline buildup.[2][3]
Pivotal moments included partnerships with Exscientia and AbCellera for drug discovery, and Phase 3 data on Chinese-sourced oncology drugs, but regulatory issues (e.g., FDA concerns on China trials) and external factors like the Inflation Reduction Act forced abandonment of the low-price strategy by 2023, culminating in layoffs and acquisition by Revolution Medicines.[1][4]
EQRx stood out in biotech through these key elements:
These aimed for Amazon-style efficiency but proved challenging amid regulatory and market realities.[2][4]
EQRx rode the biotech-tech convergence trend, applying AI/data science to pharma R&D amid rising drug costs and demands for affordability, aligning with payer pressures and value-based care.[2][3] Timing was ideal post-2019 with VC boom enabling $1B+ raises, but faltered on China trial risks (exposed by Lilly's FDA issues) and U.S. policies like the Inflation Reduction Act's pricing controls.[4] It highlighted market forces favoring efficient, tech-driven biopharma but punishing unproven disruptions—showing how execution trumps ambition in a sector with high failure rates.[4]
EQRx influenced the ecosystem by pioneering "next-gen" models, inspiring tech-biotech hybrids, though its unwind underscored barriers for outsiders challenging Big Pharma incumbents.[2][4]
Post-acquisition by Revolution Medicines in 2023, EQRx's independent story ends, with assets like its remaining CDK4/6 candidate (lerociclib) absorbed into a stronger platform amid a crowded field.[1][4] Trends like AI-accelerated discovery and pricing reforms will shape survivors, but EQRx's arc warns of overhyping process revolutions without regulatory alignment. Its legacy may evolve through Revolution Medicines advancing integrated pipelines, tying back to the original vision of efficient, patient-focused biotech—now tempered by real-world pharma dynamics.[1][4]
EQRx has raised $700.0M across 2 funding rounds. Most recently, it raised $500.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 11, 2021 | $500.0M Series B | ||
| Jan 12, 2020 | $200.0M Series A | Andreessen Horowitz, Arboretum Ventures, ARCH Venture Partners, Casdin Capital, Krishna Yeshwant, Nextech, Section 32 |